Nanox Imaging Announcement: Secures over $100M in Crossover Equity Investments

Nanox Imaging (Nanox) today reports they have secured over $100M in crossover equity investments. The news was announced today. Israeli-based A-Labs Advisory and Finance Ltd. was the lead advisor to the financing round.

The funds raised are planned to primarily support the rollout of the Nanox.ARC deployments worldwide.

The financing round was initiated in November 2019 and was delayed in closing due to the COVID-19 pandemic. Since November 2019, Nanox has signed agreements for the deployment of thousands of units of the Nanox System, its innovative medical imaging system, and diagnostics services in eleven global regions. The Company aims to revolutionize early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model to maximize the availability and accessibility of medical imaging to all socio-economic communities.

“It is easy to say that we are aiming to change the world,” says Ran Poliakine, Founder and Chief Executive Officer of Nanox. “The main challenge with such statements is always the execution. We have a bold vision to increase the early detection of medical conditions that are discoverable by X-ray. We are actively working to deploy a global medical imaging service infrastructure that may turn this dream into reality. We cannot do it without partners and investors who share our vision and support our plan. I thank our investors at SK Telecom, Foxconn, Industrial Alliance and Yozma Korea for their faith and trust in the Nanox team and vision.”

“The innovative approach of preventive healthcare and the MEMs X-ray source have driven us, The Yozma Group Asia, to invest in Nanox. Potentially reduced radiation exposure and lowered cost can set a new standard of regular health checkups,” says Wonjae Lee, Head of Asia Pacific and Managing Partner of Yozma Group. “I’m honored to be a part of the Nanox project not only because its technology is groundbreaking and contributing to mankind, but also because it’s the best example of multinational collaboration. As a strategic investor, The Yozma Group Asia is eager to make a global success case of Asian and Israeli collaboration by merging Nanox innovative technology and Korea’s outstanding manufacturing knowhow.”

 

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.